filmov
tv
ROS1 Rearrangements in mNSCLC
Показать описание
The prevalence and prognosis of ROS1 rearrangements in mNSCLC is discussed.
OncLive
cancer
oncology
Рекомендации по теме
0:03:15
ROS1 Rearrangements in mNSCLC
0:01:53
ROS-1 Rearrangements: What Are They?
0:11:47
ROS - Dr Sunil Pasricha - Interpretation Of ROS 1 Rearrangement In NSCLC
0:14:14
CRSF 7th Masterclass | 1st Line Therapy for ROS1 Rearrangement in NSCLC by Dr. Sandeep Jasuja
0:06:01
Current Management of ROS1 rearranged NSCLC
0:05:30
Sequencing Therapy in ALK/ROS1-Rearranged NSCLC
0:04:55
ROS1-Rearranged NSCLC
0:04:06
Future Directions for ROS1 rearranged mNSCLC
0:02:37
Upfront treatment of ROS1-rearranged NSCLC
0:03:55
Treatment Considerations in ALK/ROS-1–Rearranged NSCLC
0:02:58
Scientific research ROS 1 Fusion (English)
0:03:31
ALK/ROS1-Rearranged NSCLC: Approaching Therapy
0:00:56
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
0:18:41
Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities
0:01:27
Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC
0:01:53
Investigating ROS1 and TRK Rearrangements in Lung Cancer
0:04:43
Upfront Therapy for ALK/ROS1-Rearranged NSCLC
0:01:12
Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC
0:50:46
Selective, Potent, Different: Next-Generation ROS1 and TRK Inhibition in NSCLC and Other Tumors
0:08:16
TRIDENT-1: repotrectinib in ROS1-positive NSCLC
0:01:06
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
0:01:51
Dr. Riess on ROS1 Fusions in Lung Cancer
0:04:05
The Evolution of ALK/ROS1-Targeted Therapy in NSCLC
0:07:07
ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum
welcome to shbcf.ru
0:03:15
0:01:53
0:11:47
0:14:14
0:06:01
0:05:30
0:04:55
0:04:06
0:02:37
0:03:55
0:02:58
0:03:31
0:00:56
0:18:41
0:01:27
0:01:53
0:04:43
0:01:12
0:50:46
0:08:16
0:01:06
0:01:51
0:04:05
0:07:07